DrugPatentWatch Database Preview

Bristol Myers Squibb Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL MYERS SQUIBB, and when can generic versions of BRISTOL MYERS SQUIBB drugs launch?

BRISTOL MYERS SQUIBB has seventy-seven approved drugs.

There are seventeen US patents protecting BRISTOL MYERS SQUIBB drugs.

There are four hundred and forty-seven patent family members on BRISTOL MYERS SQUIBB drugs in fifty-seven countries and one hundred and seventy-six supplementary protection certificates in fifteen countries.

Summary for Bristol Myers Squibb

International Patents:	447
US Patents:	17
Tradenames:	66
Ingredients:	58
NDAs:	77

Drugs and US Patents for Bristol Myers Squibb

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-002	Jun 28, 2006	AB	RX	Yes	No
Bristol Myers Squibb	AZACTAM IN PLASTIC CONTAINER	aztreonam	INJECTABLE;INJECTION	050632-001	May 24, 1989		RX	Yes	Yes
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-003	Apr 22, 1996		DISCN	Yes	No
Bristol Myers Squibb	STILBETIN	diethylstilbestrol	TABLET, DELAYED RELEASE;ORAL	004056-012	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Bristol Myers Squibb

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	VIDEX	didanosine	TABLET, CHEWABLE;ORAL	020154-006	Oct 28, 1999	4,861,759*PED
Bristol Myers Squibb	PRAVIGARD PAC (COPACKAGED)	aspirin; pravastatin sodium	TABLET, TABLET, TABLET;ORAL	021387-005	Jun 24, 2003	4,346,227*PED
Bristol Myers Squibb	VIDEX	didanosine	FOR SOLUTION;ORAL	020155-005	Oct 9, 1991	4,861,759*PED
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-003	Sep 17, 1998	5,519,021*PED

Paragraph IV (Patent) Challenges for BRISTOL MYERS SQUIBB drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Delayed-release Capsules	200 mg, 250 mg and 400 mg		2004-06-01
	Tablets	30 mg		2005-06-01
	Capsules	100 mg and 150 mg		2010-03-19
	Tablets	0.5 mg and 1 mg		2010-06-14
	Tablets	80 mg and 140 mg		2011-06-16
	Nasal Spray	4 mg/spray		2016-07-15
	Capsules	50 mg, 100 mg and 200 mg		2016-11-03
	Tablets	600 mg		2009-04-09
	Capsules	300 mg		2009-07-20
	Capsules	200 mg		2010-02-16
	Tablets	20 mg, 50 mg, 70 mg and 100 mg		2010-06-28
	Tablets	80 mg and 140 mg		2011-06-17
	Tablets	2.5 mg and 5 mg		2016-12-28

Non-Orange Book US Patents for Bristol Myers Squibb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,382,219	Cyclic protein tyrosine kinase inhibitors
8,716,323	Cyclic protein tyrosine kinase inhibitors
6,858,616	Nitrogen containing heterobicycles as factor Xa inhibitors
7,338,963	Lactam-containing compounds and derivatives thereof as factor Xa inhibitors

International Patents for Bristol Myers Squibb Drugs

Country	Document Number	Estimated Expiration
Argentina	047533
Slovenia	1427415
China	1989969
China	101357914

Supplementary Protection Certificates for Bristol Myers Squibb Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
01C/001	Belgium		PRODUCT NAME: EFAVIRENZ; NATL. REGISTRATION NO/DATE: EU/1/99/110/001 19990604; FIRST REGISTRATION: CH 54908 01 19981120
13/34	Ireland		PRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013
/2012	Austria		PRODUCT NAME: KOMBINATIONSPRODUKT VON SAXAGLIPTIN UND METFORMIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND DIE HYDROCHLORIDSALZE VON SAXAGLIPTIN UND METFORMIN; REGISTRATION NO/DATE: EU/1/11/731/001-EU/1/11/731/012 20111124
2016039	Lithuania		PRODUCT NAME: ATAZANAVIRAS + KOBICISTATAS; REGISTRATION NO/DATE: EU/1/15/1025 20150713

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bristol
• Bristol Myers
• Bristol Myers Squibb
• Bristol-myers Squibb